Drug Trial Radar · NCT06637514
A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jul 16, 2025
Primary completion
May 8, 2026
Study completion May 8, 2026
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety. Participants will: * Take 75 mg JNT-517 or a placebo BID (2x per day) for 28 days * Visit the clinic or have a mobile health nurse visit your home for checkups and tests * Collect urine sample at home and bring to clinic on specified days * Keep a food diary 3 days before each study visit
Conditions
- Phenylketonuria (PKU)
Interventions
JNT-517 TabletDrug
JNT-517: 75 mg BID
PlaceboOther
Placebo Tablet: BID
JNT-517 TabletDrug
JNT-517: 150 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Screening to Study Completion (Average of 9 weeks)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of Florida (UF) Health Shands Hospital
Gainesville, Florida
University of South Florida
Tampa, Florida
Oregon Health and Science University
Portland, Oregon
Children's Medical Center Dallas
Dallas, Texas
University of Texas Health (UTHealth) Science Center at Houston
Houston, Texas
Utah Health - The University of Utah Hospital
Salt Lake City, Utah
Murdoch Children's Research Institute
Parkville, Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.